CAYSTON POWDER FOR SOLUTION
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
15-05-2020
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
AZTREONAM
Fáanlegur frá:
GILEAD SCIENCES CANADA INC
ATC númer:
J01DF01
INN (Alþjóðlegt nafn):
AZTREONAM
Skammtar:
75MG
Lyfjaform:
POWDER FOR SOLUTION
Samsetning:
AZTREONAM 75MG
Stjórnsýsluleið:
INHALATION
Einingar í pakka:
2ML
Gerð lyfseðils:
Prescription
Lækningarsvæði:
MONOBACTAMS
Vörulýsing:
Active ingredient group (AIG) number: 0122819004; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2009-09-11
Vara einkenni
PRODUCT MONOGRAPH
PR
CAYSTON
®
AZTREONAM FOR INHALATION SOLUTION
75 MG AZTREONAM / VIAL
ANTIBIOTIC
_(ATC J01DF01) _
_ _
_ _
_ _
_ _
_ _
Gilead Sciences, Inc.
Foster City, CA 94404
USA
Gilead Sciences Canada, Inc.
Mississauga, ON
L5N 2W3
www.gilead.ca
Control No.: 234938_ _
Date of Revision:
May 15, 2020
CAYSTON
(aztreonam for inhalation solution)
Product Monograph
2
TABLE OF CONTENTS
PART I.
HEALTH PROFESSIONAL INFORMATION
................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
6
DRUG INTERACTIONS
..............................................................................................................................
9
DOSAGE AND ADMINISTRATION
........................................................................................................
10
OVERDOSAGE
..........................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
11
STORAGE AND STABILITY
....................................................................................................................
12
SPECIAL HANDLING
INSTRUCTIONS..................................................................................................
13
DOSAGE F
Lestu allt skjalið
